EP1182207B1 - Non-covalent inhibitors of urokinase and blood vessel formation - Google Patents

Non-covalent inhibitors of urokinase and blood vessel formation Download PDF

Info

Publication number
EP1182207B1
EP1182207B1 EP00126874A EP00126874A EP1182207B1 EP 1182207 B1 EP1182207 B1 EP 1182207B1 EP 00126874 A EP00126874 A EP 00126874A EP 00126874 A EP00126874 A EP 00126874A EP 1182207 B1 EP1182207 B1 EP 1182207B1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
mmol
group
substituted
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP00126874A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1182207A2 (en
EP1182207A3 (en
Inventor
Joseph Edward Semple
Michael I. Weinhouse
Odile Ester Levy
Edwin L. Madison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heidelberg Pharma AG
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP07006986A priority Critical patent/EP1808440B1/en
Application filed by Dendreon Corp filed Critical Dendreon Corp
Priority to AU83347/01A priority patent/AU785260B2/en
Priority to CA002387002A priority patent/CA2387002A1/en
Priority to NZ518195A priority patent/NZ518195A/en
Priority to JP2002519486A priority patent/JP2004506648A/ja
Priority to NZ538572A priority patent/NZ538572A/en
Priority to PCT/US2001/025337 priority patent/WO2002014349A2/en
Priority to NZ547626A priority patent/NZ547626A/en
Priority to IL14904201A priority patent/IL149042A0/xx
Priority to KR1020027004637A priority patent/KR100879673B1/ko
Publication of EP1182207A2 publication Critical patent/EP1182207A2/en
Priority to IL149042A priority patent/IL149042A/en
Publication of EP1182207A3 publication Critical patent/EP1182207A3/en
Priority to AU2006235835A priority patent/AU2006235835B2/en
Application granted granted Critical
Publication of EP1182207B1 publication Critical patent/EP1182207B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C07K5/06069—Ser-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Urokinase is an enzyme involved in the metastasis of tumor cells, neovascularization, and other activities.
  • One purpose of the present invention is to provide novel compounds which are active as inhibitors of urokinase that can be used to inhibit the activity of urokinase and thereby attenuate its deleterious effects.
  • Another purpose of the present invention is to provide novel compounds which inhibit blood vessel formation, particularly blood vessel formation related to a pathologic condition.
  • Urinary-type plasminogen activator is a serine protease within the trypsin/chymotrypsin family. In its physiological state, uPA is found in three forms: single chain pro-uPA, two chain uPA, and low molecular weight uPA (lacks N-terminal domains). The zymogen, pro-uPA, is converted to u-PA by cleavage of the peptide bond at K158-I159. The resultant two chain uPA is linked by disulfide bridges, has an M r of about 50 kD, and a C-terminal serine proteinase domain.
  • uPA The activity of uPA is focused to cell surfaces upon binding to its receptor, uPAR.
  • uPAR is a single-chain glycosyl phosphatidyl inositol (GPI)-anchored membrane receptor.
  • GPI glycosyl phosphatidyl inositol
  • the N-terminal 92 amino acids of uPAR play a dominant role in binding to uPA and pro-uPA.
  • Receptor for uPA has been located on T-cells, NK cells, monocytes, and neutrophils, as well as vascular endothelial cells, fibroblasts, smooth muscle cells, keratinocytes, placental trophoblasts, hepatocytes, and a wide variety of tumor cells.
  • uPA After conversion of pro-uPA to uPA, which occurs primarily at the uPAR on the cell surface, uPA activates plasminogen to plasmin. Activation occurs upon cleavage at residues PGR-VV for human plasminogen, or at residues SGR-IV for bovine plasminogen. Because plasminogen also is present on the cell surface, this activation cascade focuses the activity of u-PA and plasmin on the plasma membrane. Plasmin has many roles, including activation of additional uPA and other enzymes, digestion of fibrin, and digestion of components of the extracellular matrix (ECM).
  • ECM extracellular matrix
  • the effects of the uPA system on cell migration and invasion are thought to be due to both a proteolytic effect of plasmin-mediated degradation of the extracellular matrix, as well as more a direct interaction of the uPA receptor with components of the extracellular matrix. Degradation of the extracellular matrix permits a metastasizing cell to invade the matrix, whereas interaction between uPA receptor and the matrix itself assists a cell in its migration. Localization of the uPA/plasmin system on the cell surface, or the leading edge of metastasizing cells, is consistent with postulated role of uPA in metastasis [Plesner et al ., Stem Cells 15 :398-408 (1997)].
  • uPAR Interaction of uPAR with vitronectin, a component of the extracellular matrix, mediates cell adhesion and can be enhanced when uPAR is bound by uPA.
  • Cell surface adhesion molecules, integrins also appear to be involved in this adhesion function, particularly beta-1 and beta-2 integrins [Paysant et al. , Br. J. Haematol. 100 :45-51 (1998); Simon et al., Blood 88 :3185-3194 (1996)].
  • the CD11b/CD18 integrin can associate with the uPA-uPAR complex and promote adhesion of cells bearing these receptors, e.g., neutrophils, leukocytes.
  • the uPA/uPAR system also is involved in the establishment of new vasculature, or neovascularization.
  • Pathological neovascularization also is a characteristic of retinal disease, rubeosis ulceris, proliferative vitreo retinopathy inflammatory disease, diabetic retinopathy, chronic uveitis, Fuch's heterochromic iridocyclitis, neovascular glaucoma, corneal or optic nerve neovascularization, vascular disease, pterygium, glaucoma surgery bleb failure, hyperkeratosis, cheloid and polyp formation (see EP 451,130).
  • Undesired angiogenesis also can occur in the following conditions or can be a result of the following activities: macular degeneration, retinopathy of prematurity, corneal graft rejection, retrolental fibroplasia, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, sogrens disease, acne rosacea, phylectenulosis, syphilis, Mycobacteria infections other than leprosy, lipid degeneration, chemical burns, bacterial or fungal ulcers, Herpes simplex or zoster infections, protozoan infections, Kaposi's sarcoma, Mooren ulcer, Terrien's marginal degeneration, marginal keratolysis, trauma, rheumatoid arthritis, systemic lupus, polyarteritis, Wegeners sarcoidosis, sle
  • PAI-1 and PAI-2 are members of the serpin family of proteinase inhibitors.
  • the binding of serpins to their cognate proteases involves a large number of interactions between amino acids of each protein, including those in the serpin reactive loop (Ser-Ala-Arg-Met-Ala (SEQ. ID. NO. 1) for PAI-1, Thr-Gly-Arg-Thr-Gly (SEQ. ID. NO. 2) for PAI-2).
  • Serpin reactive loop Serpin reactive loop
  • Thr-Gly-Arg-Thr-Gly SEQ. ID. NO. 2
  • Introduction of exogenous PAI-2 into experimental animals was reported to inhibit the rate of lung metastasis [Evans and Lin, Amer. Surg. 61 :692-697 (1995); Mueller et al ., Proc. Natl. Acad. Sci.
  • uPA inhibitors may be within the 4-substituted benzo[b]thiophene-2-carboxamidine class of inhibitors, of which B428 (4-iodo-benzo[b]thiophene-2-carboxamidine) and B623 are members [Towle et al., Cancer Res. 53 :2553-2559 (1993); Bridges et al., Bioorg. Med. Chem. 1 :403-410 (1993); Bridges et al., U.S. Patent No. 5,340,833].
  • B428 4-iodo-benzo[b]thiophene-2-carboxamidine
  • mice bearing tumors with B428 or B623 were said to block metastasis to muscle and fat, but did not inhibit tumor-induced angiogenesis or reduce the rate of spontaneous lung metastasis. In fact, B623 enhanced the formation of lung metastasis (Alonso et al. , Breast Cancer Res. Treat. 40 :209-223 (1996)]. Infusion of B428 in a syngeneic model of rat prostate cancer also lead to a decrease in primary tumor volume and tumor weight, and a decrease in metastasis [Rabbani et al., Int. J. Cancer 63 :840-845 (1995)].
  • uPA uPA
  • p-aminobenzamidine which is a competitive inhibitor of uPA
  • amiloride Both compounds have been shown to reduce tumor size in experimental animals [Jankan et al., Cancer Res. 57 :559-563 (1997); Billstrom et al. , Int. J. Cancer 61 :542-547 (1995)].
  • EGCG epigallo-cathecin-3 gallate
  • EGCG is a weaker inhibitor of uPA than amiloride, but suggested EGCG can be consumed in much higher doses than amiloride without toxic effect.
  • a competitive inhibitor of uPA, ⁇ -N-benzylsulfonyl-p-aminophenylalanine, is disclosed by Pye et al. in U.S. Patent No. 4,165,258.
  • Antibodies directed against uPAR, and said to inhibit the binding of uPA to UPAR, are disclosed by Dano et al. in U.S. Patent No. 5,519,120.
  • Small molecules said to inhibit urokinase, along with a variety of other serine proteases, include those disclosed by Abe et al. in U.S. Patent No. 5,508,385 and U.S. Patent No. 5,153,176, and by Takano et al. in J. Pharmacol. Exp. Therapeut. 271 :1027-1033 (1994).
  • pro-hepatocyte growth factor (HGF), a cell migration stimulating protein, is a substrate of uPA [Naldinie et al., EMBO J. 11 :4825-4833 (1992)]. Direct cleavage of a 66kDa extracellular matrix protein and fibronectin by uPA also has been reported, which suggests a more direct role for uPA in facilitating cell migration [Quigley et al., Proc. Natl. Acad. Sci. 84 :2776-2780 (1987)]. Thus, inhibition of uPA may affect these activities, as well
  • WO 00/05245 describes inhibitors of urokinase. WO 00/05245 does not disclose or suggest groups R 7 in the formula (I) below which are selected from hydrogen or alkyl.
  • EP-A-0601459 and US-A-5,932,567 describe protease inhibitors. Both EP-A-0601459 and US-A-5,932,567 envisage the use of the described compounds together with thrombolytic agents such as urokinase. Therefore, neither EP-A-0601459 nor US-A-5,932,567 suggest a modification of the described compounds to obtain inhibitors of urokinase.
  • the present invention is directed to novel pepitidic non-covalent urokinase inhibitors.
  • the compounds have an arginine mimic at P1. These compounds have activity as potent inhibitors of urokinase and thereby are useful in decreasing its deleterious effects.
  • Compounds of the present invention are active in inhibiting blood vessel formation, particularly that related to a pathologic process.
  • the present invention is directed to compounds of the formula (I): wherein:
  • the compounds of the present invention can be divided into parts termed P 1 , P 2 , P 3 and P 4 as shown in the following formula Ia: wherein X, R 1 , R 2 , R 3 , R 4 , R 7 and E are as defined in connection with formula (I).
  • P 1 or P1 the portion of a compound of formula (I) referred to as P 1 or P1 is the moiety
  • the present invention is based on our finding that the novel compounds of our invention are active as inhibitors of urokinase.
  • Compounds of the present invention exhibit activity in inhibiting angiogenesis.
  • the present invention is directed to pharmaceutical compositions comprising a therapeutically effective amount of a compound of the present invention and a pharmaceutically acceptable carrier.
  • the present invention is directed to uses of the compounds of the present invention for the preparation of pharmaceutical compositions for inhibition of urokinase.
  • alkenyl refers to unsaturated aliphatic groups having at least one double bond.
  • alkyl refers to saturated aliphatic groups including straight-chain, branched-chain and cyclic (including polycyclic) groups.
  • alkoxy and alkoxyl refer to a group having the formula, R-O-, wherein R is an alkyl group.
  • alkoxycarbonyl refers to -C(O)OR wherein R is alkyl.
  • alkenyl refers to an alkenyl group substituted with an aryl group.
  • alkenyl group has from 2 to about 6 carbon atoms.
  • aralkyl refers to an alkyl group substituted with an aryl group. Suitable aralkyl groups include benzyl, phenethyl, and the like, all of which may be optionally substituted. Preferably the alkyl group has from 1 to about 6 carbon atoms.
  • aryl refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes a carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted.
  • aryloxy refers to a group having the formula, R-O-, wherein R is an aryl group.
  • aralkoxy refers to a group having the formula, R-O-, wherein R is an aralkyl group.
  • amino acid refers to both natural, unnatural amino acids in their D and L stereo isomers if their structures allow such stereoisomeric forms, and their analogs.
  • Natural amino acids include alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr) and valine (Val).
  • Unnatural amino acids include, but are not limited to azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4 diaminoisobutyric acid, demosine, 2,2'-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, hydroxylysine, allohydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylglycine, N-methylisoleucine, N-methylvaline, norvaline, norleucine, ornithine and pipe
  • Amino acid analogs include the natural and unnatural amino acids which are chemically blocked, reversibly or irreversibly, or modified on their N-terminal amino group or their side-chain groups, as for example, methionine sulfoxide, methionine sulfone, S-(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine sulfoxide and S-(carboxymethyl)-cysteine sulfone.
  • amino acid analog refers to an amino acid wherein either the C-terminal carboxy group, the N-terminal amino group or side-chain functional group has been chemically modified to another functional group.
  • aspartic acid-(beta-methyl ester) is an amino acid analog of aspartic acid
  • N-ethylglycine is an amino acid analog of glycine
  • alanine carboxamide is an amino acid analog of alanine.
  • amino acid residue refers to radicals having the structure: (1) -C(O)-R-NH-, wherein R typically is -CH(R')-, wherein R' is H or a carbon containing substituent; or (2) wherein p is 1, 2 or 3 representing the azetidinecarboxylic acid, proline or pipecolic acid residues, respectively.
  • aryl refers to phenyl substituted by carbocyclic or heterocyclic aryl as defined herein, ortho, meta or para to the point of attachment of the phenyl ring.
  • Carbocyclic aryl refers to aromatic groups wherein the ring atoms on the aromatic ring are carbon atoms.
  • Carbocyclic aryl groups include monocyclic carbocyclic aryl groups and naphthyl groups, all of which may be optionally substituted.
  • Suitable carbocyclic aryl groups include phenyl and naphthyl.
  • Suitable substituted carbocyclic aryl groups include indene and phenyl substituted by one to two substituents such being advantageously lower alkyl, hydroxy, lower alkoxy, lower alkoxycarbonyl, halogen, trifluoromethyl, difluoromethyl, nitro, and cyano.
  • Substituted naphthyl refers to naphthyl, more preferably 1- or 2-naphthyl, substituted by Y 1 , Y 2 and/or Y 3 as defined in connection with formula (I) hereinabove.
  • Cycloalkenyl refers to a cyclic alkenyl group. Suitable cycloalkenyl groups include, for example, cyclopentenyl and cyclohexenyl.
  • Cycloalkyl refers to a cyclic alkyl group having at least one ring and includes polycyclic groups, including fused ring cyclic alkyl groups. Suitable cycloalkyl groups include, for example, cyclohexyl, cyclopropyl, cyclopentyl, and cycloheptyl.
  • Cyclohexylmethyl refers to a cyclohexyl group attached to CH 2 .
  • fused carbocyclic refers to a multicyclic fused carbocyclic ring having both aromatic and non-aromatic rings. Suitable fused carbocyclic rings include fluorenyl, tetralin and the like.
  • fused carbocyclic alkyl refers to an alkyl group substituted with a fused carbocyclic ring moiety, preferably a multicyclic fused carbocyclic ring including both aromatic and non-aromatic rings. Suitable fused carbocyclic alkyl groups include fluorenylmethyl, and the like.
  • halogen refers to fluorine, chlorine, bromine and iodine.
  • Heteroaralkenyl refers to an alkenyl group substituted with a heteroaryl, and includes those heterocyclic systems described in "Handbook of Chemistry and Physics", 49th edition, 1968, R.C. Weast, editor; The Chemical Rubber Co., Cleveland, OH. See particularly Section C, Rules for Naming Organic Compounds, B. Fundamental Heterocyclic Systems.
  • the alkenyl group has from 2 to about 6 carbon atoms.
  • Heteroaralkyl refers to an alkyl group substituted with a heteroaryl, such as picolyl, and includes those heterocyclic systems described in "Handbook of Chemistry and Physics", 49th edition, 1968, R.C. Weast, editor; The Chemical Rubber Co., Cleveland, OH. See particularly Section C, Rules for Naming Organic Compounds, B. Fundamental Heterocyclic Systems.
  • the alkyl group has from 1 to about 6 carbon atoms.
  • Heteroaryl refers to aromatic groups having from 1 to 14 carbon atoms and the remainder of the ring atoms are heteroatoms, and includes those heterocyclic systems described in "Handbook of Chemistry and Physics", 49th edition, 1968, R.C. Weast, editor; The Chemical Rubber Co., Cleveland, OH. See particularly Section C, Rules for Naming Organic Compounds, B. Fundamental Heterocyclic Systems.
  • Suitable heteroatoms include oxygen, nitrogen, and S(O) i , wherein i is 0, 1 or 2
  • suitable heterocyclic aryls include furanyl, thienyl, pyridyl, pyrrolyl, pyrimidyl, pyrazinyl, imidazolyl, and the like.
  • Heterocyclo refers to a reduced heterocyclic ring system comprised of carbon, nitrogen, oxygen and/or sulfur atoms, and includes those heterocyclic systems described in "Handbook of Chemistry and Physics", 49th edition, 1968, R.C. Weast, editor; The Chemical Rubber Co., Cleveland, OH. See particularly Section C, Rules for Naming Organic Compounds, B. Fundamental Heterocyclic Systems.
  • Heterocycloalkyl refers to an alkyl group substituted with a heterocyclo group, and includes those heterocyclic systems described in "Handbook of Chemistry and Physics", 49th edition, 1968, R.C. Weast, editor; The Chemical Rubber Co., Cleveland, OH. See particularly Section C, Rules for Naming Organic Compounds, B. Fundamental Heterocyclic Systems.
  • the alkyl group has from about 1 to about 6 carbon atoms.
  • radicals or groups with one and up to and including 5 carbon atoms, preferably up to and including 4 carbon atoms, and advantageously one or two carbon atoms.
  • Such radicals or groups may be straight chain or branched chain.
  • Perfluoroalkyl refers to an alkyl group which has every hydrogen replaced with fluorine.
  • Perfluoroaryl refers to an aryl group which has every hydrogen replaced with fluorine.
  • Perfluoroarylalkyl refers to an aralkyl group in which every hydrogen on the aryl moiety is replaced with fluorine.
  • “Pharmaceutically acceptable salt” includes salts of the compounds of the present invention derived from the combination of such compounds and an organic or inorganic acid. In practice the use of the salt form amounts to use of the base form. The compounds of the present invention are useful in both free base and salt form, with both forms being considered as being within the scope of the present invention.
  • AIBN refers to 2, 2'-azobisisobutyronitrile.
  • Boc refers to t-butoxycarbonyl
  • Boc 2 O refers to Boc anhydride (di-tert-butyl carbonate).
  • Cbz or “CBz” refers to benzyloxycarbonyl.
  • CsCo 3 refers to cesium carbonate.
  • DCA dichloroacetic acid
  • DCC refers to N,N'-dicyclohexylcarbodiimide.
  • DCM dichloromethane
  • DIEA diisopropylethylamine
  • DMF N,N-dimethylformamide
  • DMSO dimethyl sulfoxide
  • DMAP refers to 4-N,N-dimethylaminopyridine.
  • EDC refers to 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide hydrochloride salt.
  • Et 3 N or “TEA” refers to triethylamine.
  • EtOAc refers to ethyl acetate
  • HATU refers to O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluromium hexafluorophosphate.
  • HBTU refers to 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate.
  • HCl refers to hydrochloric acid
  • HOAc refers to acetic acid
  • HAT or "HOAT” refers to 1-hydroxy-7-azabenzotriazole.
  • HOBt refers to 1-hydroxybenzotriazole monohydrate.
  • i-BuOCOCl refers to isobutylchloroformate.
  • HPLC refers to high pressure liquid chromatography.
  • LiAlH 4 refers to lithium aluminum hydride.
  • LiAlH 2 (OEt) 2 refers to lithium aluminum hydride diethoxide.
  • Me refers to methyl
  • MeOH refers to methanol
  • NMM refers to N-methylmorpholine.
  • PhB(OH) 2 refers to phenylboronic acid.
  • PyBOP refers to benzotriazole-ly-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate.
  • RP-HPLC refers to reverse phase high pressure liquid chromatography.
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • TLC refers to thin layer chromatography
  • R 1 groups include alkyls, especially isobutyl, 2-ethylhexyl, methyl, n-butyl, isopropyl, cyclohexylmethyl, and cyclohexylpropyl; cycloalkyl, especially (-)menthyl, (+)menthyl, and cyclohexyl; aryls, especially naphthyl and phenyl, aralkyls, especially benzyl, 3-phenylpropyl, and 2-phenylethyl; and fused carbocyclic alkyls, especially fluorenylmethyl.
  • Especially preferred R 1 groups include phenyl, benzyl, 2-phenylethyl, isobutyl, n-butyl and 3-phenylpropyl.
  • R 2 groups are CH(R 5 )OH, wherein R 5 is hydrogen or methyl.
  • Preferred chirality at the alpha carbon is R.
  • preferred chirality at the beta carbon is R:
  • Preferred R 2 groups are those that define the P 3 position as d-seryl (-CH(R 5 )OH where R 5 is H), (R,R)d-allothreonyl (-CH(R 5 )OH where R 5 is methyl).
  • Especially preferred R 2 groups are those which define P 3 as d-seryl (R 5 is H) or (R,R) d-allothreonyl (R 5 is methyl).
  • R 2 groups include -(CH 2 ) 2 OA 1 and -CH(R 5 )OA 1 , more preferably -CH(R 5 )OA 1 ; preferably R 5 is H. More preferably R 2 is selected so that P 3 is defined as an acyl or carbonate ester of d-seryl. Compounds wherein R 2 is -(CH 2 ) 2 OA 1 or -CH(R 5 )OA 1 may act as prodrugs.
  • R 3 group when R 3 and R 4 are not selected together, which is hydrogen.
  • R 4 group which, when R 3 and R 4 are not selected together, is methyl, vinyl, allyl or propargyl.
  • R 3 and R 4 are selected together, to be prolyl, 3-hydroxy-prolyl, 4-hydroxyprylyl, 3,4-dehydroprolyl, 3,4-methanoprolyl, and azetidine-2-carbonyl- and define a group at P2.
  • Preferred R 7 groups include hydrogen.
  • Preferred E groups include 4-amidinophenyl, 4-guanidinophenyl, 3-amidinopropyl, and 5-(2-amidino-thienyl).
  • preferred compounds include those having an R 2 element that defines d-serine or d-allothreonine or an acyl or carbonate ester thereof at the P3 position of the compound and an amidinophenyl, guanidinophenyl or amidinothiehyl group at P1.
  • R 3 and R 4 selected together so that P2 is prolyl, azetidine-2-carbonyl, 3,4-methanoprolyl or 3,4-dehydroprolyl.
  • Preferred compounds of the present invention include those depicted in Figures 10A to 10F. Especially preferred are Compounds D, F, I, J, K, L. O, R, T, U, V, AE, AH, AJ, AN and AV of Figures 10A to 10F.
  • the substitutions are to be made with respect to formula I.
  • Figures 1 to 5 depict synthetic schemes for synthesis of intermediates which may be used in preparation of certain compounds of the present invention.
  • Figure 1 depicts solution phase synthesis of intermediates useful in the preparation of compounds of the present invention. See Examples 60 to 62. See also Examples 95 to 97.
  • Examples 63 to 66, 67 to 70 and 71 to 73 describe solution phase syntheses of intermediates useful in the synthesis of compounds of the present invention.
  • Figure 2 depicts an alternate synthetic route to prepare an intermediate useful in the preparation of compounds of the present invention using solution phase synthesis. See also Examples 74 to 76.
  • Figure 6 depicts a reaction scheme for the preparation of a compound of the present invention having an esterified hydroxyl at P3.
  • Figure 7 depicts a reaction scheme for the preparation of a compound of the present invention having a 4-guanidinophenyl at P1.
  • Figure 8 depicts a reaction scheme for the preparation of a compound of the present invention having a 3-guanidinophenyl at P1.
  • Figure 9 depicts a reaction scheme for the preparation of a compound of the present invention having 2-guanidinothiophenyl at P1.
  • Figure 11 depicts a reaction scheme for the preparation of a compound of the present invention having a 3-amidinopyridyl at P1.
  • Preferred means of chemically coupling include formation of a peptide bond by using conventional coupling reagents known in the art. See Bodanszky, N. Peptide Chemistry., pp. 55-73, Springer-Verlag, New York (1988) and references cited therein.
  • the chemical coupling may be either by means of one-step or two-step coupling.
  • one-step coupling the two coupling partners are coupled directly.
  • Preferred coupling reagents for one-step coupling of the coupling partners include DCC with HOBt, EDC with HOBt, EDC with HOAt, HBTU or TBTU.
  • an activated ester or anhydride of the C-terminal carboxy group of one coupling partner is formed prior to its coupling to the other coupling partner.
  • Another preferred method for preparing compounds of the present invention containing hydrogenation sensitive groups such as alkenyl or aryl moieties substituted with halogen, cyano, nitro, or -S-Z 1 , is to use boron tris(trifluoroacetate), B(OCOCF 3 ) 3 , to cleave the N g -nitro of the arginine group.
  • the reagent is prepared by the reaction of BBr 3 and CF 3 COOH in dichloromethane at 0°C. The reagent is also commercially available.
  • the N g -nitro compound is treated with boron tris(trifluoroacetate) in trifluoroacetic acid at 0°C.
  • boron tris(trifluoroacetate) in trifluoroacetic acid at 0°C. See, e.g., Fieser, M. and Fieser, L. F., Reagents for Organic Synthesis, p. 46, John Wiley & Sons, New York (1974); Pless, J., and Bauer, W. Angew. Chem., Internat. Ed., 12, 147 (1973).
  • titanium trichloride is another preferred reagent for selective nitro group cleavage.
  • This reagent is commercially available.
  • the N g nitro compound is treated with titanium trichloride in aqueous methanol containing an ammonium acetate buffer followed by exposure of the reaction mixture to air or dimethyl sulfoxide. See, e.g. , Freidinger, R.M., Hirschmann, R., and Veber, D.F., J. Org. Chem., 43, 4800 (1978).
  • An intermediate such as 6-1 (the compound of Example 9) is reacted with an acid chloride R 6 COCl in the presence of a base such as pyridine.
  • R 2 is -(CH 2 ) 2 OH or -CH(R 5 )OH
  • it may be preferred to cap the P3 hydroxyl with the carbonate group prior to deprotecting the amidino or guanidino group.
  • the product is then hydrogenated and optionally treated under hydrolysis conditions to yield the product. (See, e.g. , Examples 16, 21, 28, 35 and 40.)
  • preferred compounds of the present invention are selected for their potency and selectivity toward inhibition of serine proteases, especially urokinase.
  • Such evaluations are routinely performed in vitro, following procedures such as those set forth in Example A.
  • a target serine protease and its substrate are combined under assay conditions permitting reaction of the protease with its substrate.
  • the assay is performed in the absence of test compound, and in the presence of increasing concentrations of the test compound.
  • the concentration of test compound at which 50% of the serine protease activity is inhibited by the test compound is the IC 50 value (Inhibitory Concentration) or EC 50 (Effective Concentration) value for that compound.
  • IC 50 or EC 50 values are considered more potent inhibitors of the serine protease than those compounds having higher IC 50 or EC 50 values.
  • the IC 50 measurement is often used for more simplistic assays, whereas the EC 50 is often used for more complicated assays, such as those employing cells.
  • K i is calculated from the IC 50 .
  • Preferred compounds according to this aspect of the present invention have a K i value of 100nM or less as measured in an in vitro assay for inhibition of urokinase activity. Especially preferred compounds have a K i value of less than 30nM.
  • test compounds also are evaluated for selectivity toward a serine protease.
  • a test compound is assayed for its potency toward a panel of serine proteases and other enzymes and an IC 50 value or EC 50 value is determined for each test compound in each assay system.
  • a compound that demonstrates a low IC 50 value or EC 50 value or corresponding low K i value for the target enzyme, e.g. , urokinase, and a higher IC 50 value or EC 50 value for other enzymes within the test panel e.g. , tissue plasminogen activator, thrombin, Factor Xa
  • tissue plasminogen activator e.g. , thrombin, Factor Xa
  • a compound is deemed selective if its IC 50 value or EC 50 value (or K i value) in the target enzyme assay is at least one order of magnitude less than the next smallest IC 50 value or EC 50 value measured in the selectivity panel of enzymes.
  • Preferred compounds of the present invention have a K i value of 100nM or less as measured in an in vitro assay for inhibition of urokinase activity.
  • Especially preferred compounds have a K i value in the in vitro urokinase inhibition assay that is at least one order of magnitude smaller than the IC 50 value measured in the in vitro tPA inhibition assay.
  • Compounds having a selectivity ratio of IC 50 tPA assay: K i urokinase assay of greater than 100 are especially preferred.
  • Compounds of the present invention also are evaluated for their activity in vivo .
  • the type of assay chosen for evaluation of test compounds will depend on the pathological condition to be treated or prevented by use of the compound, as well as the route of administration to be evaluated for the test compound.
  • the procedures described by Jankun et al. [Canc. Res. 57 :559-563, 1997] to evaluate PAI-1 can be employed. Briefly, the ATCC cell lines DU145, which expresses a high level of uPA, and LnCaP, which does not express uPA, are injected into SCID mice. After tumors are established, the mice are given test compound according to a dosing regime determined from the compound's in vitro characteristics. The Jankun et al. compound was administered in water. Tumor volume measurements are taken twice a week for about five weeks.
  • a compound is deemed active if an animal to which the compound was administered exhibited decreased tumor volume, as compared to animals receiving appropriate control compounds. Furthermore, a comparison of a compound's effect in animals injected with DU145 cells versus LnCaP cells can indicate whether the compound's effect was due to inhibition of urokinase or otherwise.
  • a murine xenograft selected for high lung colonization potential is injected into C57B1/6 mice i.v. (experimental metastasis) or s.c. into the abdominal wall (spontaneous metastasis).
  • Various concentrations of the compound to be tested can be admixed with the tumor cells in Matrigel prior to injection.
  • Daily i.p. injections of the test compound are made either on days 1-6 or days 7-13 after tumor inoculation.
  • the animals are killed about three or four weeks after tumor inoculation, and the lung tumor colonies are counted. Evaluation of the resulting data permits a determination as to efficacy of the test compound, optimal dosing and route of administration.
  • the activity of the compounds of the present invention toward decreasing tumor volume and metastasis can be evaluated in the model described by Rabbani et al. [Int. J. Cancer 63 :840-845, 1995] to evaluate their inhibitor.
  • Mat LyLu tumor cells over-expressing uPA were injected into the flank of Copenhagen rats.
  • the animals were implanted with osmotic minipumps to continuously administer various doses of test compound for up to three weeks.
  • the tumor mass and volume of experimental and control animals were evaluated during the experiment, as were metastatic growths. Evaluation of the resulting data permits a determination as to efficacy of the test compound, optimal dosing, and route of administration.
  • a rabbit cornea neovascularization model can be employed.
  • Avery et al. describe anesthetizing New Zealand albino rabbits and then making a central corneal incision and forming a radial corneal pocket.
  • a slow release prostaglandin pellet was placed in the pocket to induce neovascularization.
  • Test compound was administered i.p. for five days, at which time the animals were killed. The effect of the test compound is evaluated by review of periodic photographs taken of the limbus, which can be used to calculate the area of neovascular response and, therefore, limbal neovascularization.
  • a decreased area of neovascularization as compared with appropriate controls indicates the test compound was effective at decreasing or inhibiting neovascularatization.
  • An angiogenesis model used to evaluate the effect of a test compound in preventing angiogenesis is described by Min et al . [Canc. Res. 56 :2428-2433, 1996].
  • C57BL6 mice receive subcutaneous injections of a Matrigel mixture containing bFGF, as the angiogenesis-inducing agent, with and without test compound. After five days, the animals are killed and the Matrigel plugs, in which neovascularization can be visualized, are photographed.
  • An experimental animal receiving Matrigel and an effective dose of test compound will exhibit less vascularization than a control animal or an experimental animal receiving a less- or non-effective dose of compound.
  • the CAM model (chick embryo chorioallantoic membrane model), first described by L. Ossowski in 1998 [J. Cell Biol. 107 :2437-2445, 1988], provides another method for evaluating the urokinase inhibitory activity of a test compound.
  • invasion of tumor cells through the chorioallantoic membrane is dependent upon the presence of catalytically active uPA.
  • Contacting CAM with tumor cells in the presence of a urokinase inhibitory agent results in less or no invasion of the tumor cells through the membrane.
  • the CAM assay is performed with CAM and tumor cells in the presence and absence of various concentrations of test compound. The invasiveness of tumor cells is measured under such conditions to provide an indication of the compound's urokinase inhibitory activity.
  • a compound having urokinase inhibitory activity correlates with less tumor invasion.
  • the CAM model is also used in a standard assay of angiogenesis (i.e., effect on formation of new blood vessels (Brooks, P.C.; Montgomery, A.M.P.; and Cheresh, D.A., Methods in Molecular Biology 129: 257-269 (1999)).
  • angiogenesis inducer such as basic fibroblast growth factor (bFGF) is placed onto the CAM. Diffusion of the cytokine into the CAM induces local angiogenesis, which may be measured in several ways such as by counting the number of blood vessel branch points within the CAM directly below the filter disc.
  • bFGF basic fibroblast growth factor
  • a test compound can either be added to the filter disc that contains the angiogenesis inducer, be placed directly on the membrane or be administered systemically. The extent of new blood vessel formation in the presence and/or absence of test compound can be compared using this model. The formation of fewer new blood vessels in the presence of a test compound would be indicative of anti-angiogenesis activity. Since certain of the compounds of the present invention are active as inhibitors of urokinase, anti-angiogenesis activity for such compounds may suggest that urokinase plays a significant role in angiogenesis.
  • the present invention encompasses pharmaceutical compositions prepared for storage or administration which comprise a therapeutically effective amount of a compound of the present invention in a pharmaceutically acceptable carrier.
  • the therapeutically effective amount of a compound of the present invention will depend on the route of administration, the type of mammal being treated, and the physical characteristics of the specific mammal under consideration. These factors and their relationship to determining this amount are well known to skilled practitioners in the medical arts. This amount and the method of administration can be tailored to achieve optimal efficacy but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize.
  • the therapeutically effective amount of the compound of the present invention can range broadly depending upon the desired affects and the therapeutic indication. Typically, dosages will be between about 0.01 mg/kg and 100 mg/kg body weight, preferably between about 0.01 and 10 mg/kg, body weight.
  • Pharmaceutically acceptable carriers for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A.R. Gennaro edit. 1985).
  • sterile saline and phosphate-buffered saline at physiological pH may be used.
  • Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition.
  • sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives. Id. at 1449.
  • antioxidants and suspending agents may be used. Id .
  • compositions of the present invention may be formulated and used as tablets, capsules or elixirs for oral administration; suppositories for rectal administration; sterile solutions and suspensions for injectable administration; and the like.
  • the dose and method of administration can be tailored to achieve optimal efficacy but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize.
  • injectable pharmaceutical compositions can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
  • Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, or the like.
  • the injectable pharmaceutical compositions may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like.
  • absorption enhancing preparations e.g., liposomes may be utilized.
  • the compounds of the present invention having urokinase inhibitory activity and/or activity in reducing or inhibiting blood vessel formation, including angiogenesis and neovascularization, may be used both in vitro and in vivo for a number of applications, some of which are described herein below.
  • the compounds of the present invention are active as inhibitors of urokinase and specifically bind urokinase. Accordingly those compounds that contain sites suitable for linking to a solid/gel support may be used in vitro for affinity chromatography to purify urokinase from a sample or to: remove urokinase from a sample using conventional affinity chromatography procedures. These compounds are attached or coupled to an affinity chromatography either directly or through a suitable linker support using conventional methods. See, e.g. Current Protocols in Protein Science, John Wiley & Sons (J.E. Coligan et al., eds, 1997) and Protein Purification Protocols, Humana Press (S. Doonan, ed., 1966) and references therein.
  • the compounds of the present invention having urokinase inhibitory activity are useful in in vitro assays to measure tPA activity in a sample.
  • assays which measure the total plasminogen activation activity in a blood sample a compound of the present invention having urokinase inhibiting activity will knock out that portion of plasminogen activation attributable to uPA, which will allow for calculation of the portion of the total plasminogen activation due to tPA activity as well as that due to uPA activity.
  • Use of such assays to monitor tPA activity would allow better dosage control in patients receiving tPA.
  • These assays could also be used to monitor uPA activity levels in tissue samples, such as from biopsy or to monitor uPA/tPA activities for any clinical situation where measurement of plasminogen activation activity is of assistance. These assays may also be used to monitor plasminogen activator activity where a patient has been treated with a non-endogenous compound having plasminogen activator activity, such as streptokinase and staphlyokinase.
  • the compounds of the present invention are useful in vivo for treatment of pathologic conditions which would be ameliorated by decreased urokinase activity.
  • these compounds will inhibit the activation of metalloproteases by the uPA-plasmin cascade in synovial fluid and thus, may be used in treatment of arthritis.
  • these compounds will be useful in decreasing or inhibiting metastasis, neovascularization, and degradation of the extracellular matrix in tumors and other neoplasms. These compounds will be useful as therapeutic agents in treating conditions characterized by pathological neovascularation such as retinal disease, retinopathies and other conditions, including those described hereinabove in the Background and Introduction to the Invention.
  • Another use for the compounds of the present invention having urokinase inhibitory activity is as an antidote if too much exogenous urokinase has been given to a patient for therewith purposes, such as for dissolving a blood clot.
  • the compounds of the present invention may be used in treating conditions characterized by inflammation due to their anti-inflammatory effects from inhibition of urokinase, thereby interfering with mediators of cell adhesion or migration.
  • Such anti-inflammatory applications include treatment of stroke and complications of organ transplants.
  • the present invention includes methods for preventing or treating a condition in a mammal suspected of having a condition which will be attenuated by inhibition of urokinase activity comprising administering to said mammal a therapeutically effective amount of a compound or a pharmaceutical composition of the present invention.
  • the compounds or pharmaceutical compositions of the present invention are administered in vivo , ordinarily in a mammal, preferably in a human.
  • the compounds or pharmaceutical compositions can be administered to a mammal in a variety of ways, including orally, parenterally, intravenously, subcutaneously, intramuscularly, colonically, rectally, nasally or intraperitoneally, employing a variety of dosage forms.
  • Administration is preferably oral, such as by tablets capsules or elixirs taken on a daily basis.
  • the compounds or pharmaceutical compositions of the present invention are administered alone or in combination with one another, or in combination with other therapeutic or in vivo diagnostic agents.
  • a "therapeutically effective amount" of the compounds or pharmaceutical compositions of the present invention will vary depending upon the age, weight and mammalian species treated, the particular compounds employed, the particular mode of administration and the desired affects and the therapeutic indication. Because these factors and their relationship to determining this amount are well known in the medical arts, the determination of therapeutically effective dosage levels, the amount necessary to achieve the desired result of inhibiting uPA activity, will be within the ambit of one skilled in these arts. Typically, administration of the compounds or pharmaceutical composition of the present invention is commenced at lower dosage levels, with dosage levels being increased until the desired effect of inhibiting uPA activity to the desired extent is achieved, which would define a therapeutically effective amount. For the compounds of the present invention, alone or as part of a pharmaceutical composition, such doses are between about 0.01 mg/kg and 100 mg/kg body weight, preferably between about 0.01 mg/kg and 10 mg/kg, body weight.
  • Example 7 To a solution of the product in Example 7 (117 mg, 0.285 mmol) in 1.14 ml methanol was added hydroxylamine hydrochloride (33.7 mg, 0.485 mmol), followed by N-methylmorpholine (53 ⁇ l, 0.485 mmol). The reaction mixture was stirred overnight at ambient temperature and then at 50°C for six hours. The reaction mixture was concentrated in vacuo. The crude product was taken to the next step (Example 9) without further purification. The product eluted at 6.5 minutes by reverse phase (C18) HPLC at 0.1% trifluoroacetic acid in 5-50% aqueous acetonitrile over 20 minutes.
  • hydroxylamine hydrochloride 33.7 mg, 0.485 mmol
  • N-methylmorpholine 53 ⁇ l, 0.485 mmol
  • Example 8 To the product of Example 8 (126 mg, 0.285 mmol) in acetic acid (2.85 ml) and water (0.28 ml) was added 185 mg activated zinc dust. The reaction mixture was stirred overnight at room temperature. The zinc dust was filtered using a glass funnel and the filtrate was purified by preparative HPLC. The fractions containing the product eluted in a 5-20% aqueous acetonitrile containing 0.1% TFA and were pooled and lyophilized yielding 35 mg of the title compound as a white powder. The product eluted at 6.0 minutes by reverse phase (C18) HPLC at 0.1% trifluoroacetic acid in 5-50% aqueous acetonitrile over 20 minutes.
  • C18 reverse phase
  • Example 15 To a solution of the product in Example 15 (143 mg, 0.305 mmol) in 1.22 ml methanol was added hydroxylamine hydrochloride (0.036 mg, 0.519 mmol) followed by N-methylmorpholine (57 ⁇ l, 0.519 mmol). The reaction mixture was stirred over night at ambient temperature. Analytical HPLC suggested that the reaction was not complete. Additional hydroxylamine hydrochloride (0.036 mg, 0.519 mmol) and N-methylmorpholine (57
  • Example 16 To the product of Example 16 (15 mg, 0.030 mmol) in acetic acid (0.30 ml) and water (0.03 ml) was added 19 mg activated zinc dust. The reaction mixture was stirred over night at room temperature. The zinc dust was filtered using a glass funnel and the filtrate was purified by preparative HPLC. The fractions containing the product eluted in a 5-20% aqueous acetonitrile containing 0.1% TFA, and were pooled and lyophilized yielding 7 mg of the title compound as a white powder. The product eluted at minutes by reverse phase (C18) HPLC at 0.1% trifluoroacetic acid in 5-50% aqueous acetonitrile over 20 minutes.
  • C18 reverse phase
  • Example 21 The compound of Example 21 (114 mg, 0.17 mmol) was dissolved in methanol (15 ml) and was hydrogenated on a Parr shaker overnight at 40 psi in the presence of 15 mg palladium on charcoal. The catalyst was filtered off. The reaction mixture was diluted to 35 ml with water and purified by preparative HPLC. The fractions containing the product eluted in 0-25% aqueous acetonitrile containing 0.1% TFA and were pooled and lyophilized yielding 16 mg of the title compound as a white powder.
  • Triphenylphosphine (Aldrich, 5.7 g) was added to a solution of 2-cyano-5-(azidomethyl)thiophene (compound 25, 2.5 g, 10 mmol) in THF (Aldrich, 40 ml) and water (10 ml) at 0°C. The resulting solution was allowed to warm to room temperature and stirred at ambient temperature for 10 hours. RP HPLC purification led to the title compound (2.3 g, 94%).
  • Example 28 To the product of Example 28 (60 mg, 0.13 mmol) in acetic acid (1.3 ml) and water (0.13 ml) was added 87 mg activated zinc dust. The reaction mixture was stirred overnight at ambient temperature. The zinc dust was filtered using a glass funnel and the filtrate was purified by preparative HPLC. The fractions containing the product eluted in 0-20% aqueous acetonitrile containing 0.1% TFA. They were pooled and lyophilized yielding 7 mg of the title compound as a white powder.
  • step A ( b ))(3 grams, 14.76 mmol) in methanol (120 ml) and concentrated HCl (1.5 ml) with 10% Pd/C (300 mg) was hydrogenated at 50 psi for 16 hours.
  • the reaction mixture was filtered to remove the carbon-based catalyst and the filtrate was concentrated.
  • the residue was dissolved in water/dioxane (100 ml) and diisopropylethylamine (3.2 ml) was added.
  • Benzyl chloroformate (2.76 ml, 16.2 mmol) was added and the reaction mixture was stirred overnight.
  • N-benzyloxycarbonyl-3,4-methanoproline obtained in step C, above
  • ethanol 47 ml
  • 0.5M HCl 9.42 ml
  • the reaction mixture was hydrogenated at atmospheric pressure overnight.
  • the catalyst was filtered off and the filtrate was concentrated in vacuo to yield 767 mg pure product.
  • the product eluted at 14 minutes by reverse phase (C18) HPLC at 0.1% trifluoroacetic acid in 5-75% aqueous acetonitrile over 20 minutes.
  • step E A solution of the compound of Example 30 (step E) (0.70 g, 3.082 mmol), p-cyanobenzylamine hydrochloride salt (0.784 g, 4.62 mmol), EDC (0.88 g, 4.62 mmol), N-hydroxybenzotriazole (0.47 g, 3.082 mmol) and diisopropylethylamine (2.68 ml, 15.41 mmol) was stirred in acetonitrile (12 ml) at ambient temperature.
  • Example 34 To a solution of the product in Example 34 (154 mg, 0.32 mmol) in 1.3 ml methanol was added hydroxylamine hydrochloride (0.11 g, 1.58 mmol) followed by N-methylmorpholine (209 ⁇ l, 1.902 mmol). The reaction mixture was stirred overnight at ambient temperature. The reaction mixture was concentrated in vacuo . The crude product was resuspended in 25% acetonitrile in water and purified by preparative HPLC. The fractions containing the product eluting in 0-20% aqueous acetonitrile containing 0.1% TFA solution were pooled and lyophilized yielding 19.5 mg of the title compound as a white powder. Low resolution mass spectroscopy confirmed the desired mass (MH + 516).
  • Example 35 To the product of Example 35 (19.5 mg, 0.041 mmol) in acetic acid (0.41 ml) and water (0.041 ml) was added 27 mg activated zinc dust. The reaction mixture was stirred over night at room temperature. The zinc dust was filtered using a glass funnel and the filtrate was purified by preparative HPLC. The fractions containing the product eluting in 0-20% aqueous acetonitrile containing 0.1% TFA were pooled and lyophilized yielding 15 mg of the title compound as a white powder. The product eluted at 10.5 minutes by reverse phase (C18) HPLC at 0.1% trifluoroacetic acid in 5-50% aqueous acetonitrile over 20 minutes. Low resolution mass spectroscopy confirmed the desired mass (MH + 500).
  • 3-Nitrobenzylamine (8-1) (3.0 g, 16 mmol) was added in portions to stirring trifluoroacetic anhydride (30 ml) while the mixture was being cooled on ice, and the mixture stirred overnight.
  • the suspension was poured onto ice (approximately 200 g) and the cloudy suspension was extracted with CH 2 Cl 2 (2 x 100 ml) dried over Na 2 SO 4 and the solvent removed to give a transparent oil.
  • This oil was shaken in a Parr flask with Pd/C (10%, 300 mg) in MeOH (30 ml) overnight. The solid was removed by filtration and the solvent removed in vacuo to give a white solid corresponding to the title compound (3.3 g, 95%).
  • Example 55 The compound of Example 55 ( 11-7 ) (229 mg, 0.74 mmol) was dissolved in dioxane (1 ml) and treated with a solution of 4N HCl in dioxane (1 ml) for one hour at room temperature. Removal of the solvent under reduced pressure afforded 290 mg of a white solid. That product was then dissolved in acetonitrile (4.12 ml), neutralized with diisopropylethylamine (538 ⁇ l, 3.09 mmol) and coupled to Boc-alanine (195 mg, 1.03 mmol) using EDC (197 mg, 1.03 mmol) and HOBt (157.6 mg, 1.03 mmol) as coupling reagents.
  • Example 56 The compound of Example 56 ( 11-8 ) (181 mg, 0.48 mmol) was dissolved in dioxane (1 ml) and treated with 4N HCl in dioxane (1 ml) for 1.5 hour at room temperature. Removal of the solvent under reduced pressure afforded 200 mg of a white solid. That product was then dissolved in acetonitrile (5 ml), neutralized with diisopropylethylamine (298 ⁇ l, 1.71 mmol) and coupled to BnSO 2 -dSer(tBu)-OH (180 mg, 0.57 mmol), using EDC (109 mg, 0.57 mmol) and HOBt (96 mg, 0.63 mmol) as coupling reagents.
  • Example 57 The compound of Example 57 ( 11-9 ) (137 mg, 0.24 mmol) was treated with 2 ml each dichloromethane and trifluoroacetic acid for one hour at room temperature. Removal of the solvent under reduced pressure afforded 169 mg of an orangish oil. The product eluted at 9 minutes by reverse phase (C18) HPLC at 0.1% trifluoroacetic acid in 5-90% aqueous acetonitrile over 20 minutes.
  • C18 reverse phase
  • Example 58 The product of Example 58 ( 11-10 ) (74 mg, 0.14 mmol) in water (8 ml) and acetic acid (0.8 ml) was treated with activated zinc dust (91 mg) for 45 minutes. The solution was filtered and the filtrate was subjected to purification by reverse phase HPLC (C18). The product eluted at 11 minutes by reverse phase HPLC at 0.1% trifluoroacetic acid in 5-25% aqueous acetonitrile over 20 minutes. MS (electrospray): 463 (M + 1).
  • N- ⁇ -Cbz-D-serine ( 1-1 ) (Bachem, 4.97 g, 16.8 mmol), alanine methyl ester, hydrochloride salt (1-2) (Novabiochem, 4.7 g, 33.7 mmol), EDC (6.5 g, 33.7 mmol), and 1-hydroxybenzotriazole (2.6 g, 16.8 mmol) were combined, and acetonitrile (67 ml) was added. After stirring as a slurry for 10 minutes, diisopropylethylamine (14.4 ml, 84 mmol) was added, and the resulting clear mixture was stirred for an additional 18 hours.
  • Example 61 To the compound of Example 61 ( 1-4 ) (0.53 g, 1.4 mmol) in methanol (9 ml) was added 1.0M lithium hydroxide (3.0 ml, 3 mmol). After stirring for 18 hours, the reaction mixture was poured over a column of 10 ml of DOWEX (50 X 8-400) ion exchange resin, and eluted with methanol/water (60 ml of a 1:1 mixture).
  • DOWEX 50 X 8-400
  • Example 64 The compound of Example 64 (1.0 g, 3.2 mmol), alanine methyl ester, hydrochloride salt (Novabiochem, 0.89 g, 6.3 mmol), EDC (1.22 g, 6.3 mmol), and 1-hydroxybenzotriazole (0.49 g, 3.2 mmol) were combined and acetonitrile (13 ml) was added. After stirring the resulting slurry for 10 minutes, diisopropylethylamine (2.71 ml, 15.8 mmol) was added and the resulting clear mixture was stirred for an additional 18 hours. The solvent was removed under reduced pressure, and the residue was suspended in ethyl acetate (100 ml).
  • Example 65 To the compound of Example 65 (1.22 g, 3.1 mmol) in methanol (22 ml), was added 1M lithium hydroxide (7.2 ml, 7.2 mmol). After stirring 18 hours, the reaction mixture was poured over a column of 10 ml of DOWEX (50 X 8-400) ion exchange resin and eluted with methanol:water (60 ml of a 1:1 mixture). The methanol was removed under reduced pressure, and the aqueous solution was lyophilized to afford 1.16 g of the title compound in 91% yield.
  • t R 13.2 minutes (0.1% trifluoroacetic acid in 5-75% aqueous acetonitrile over 20 minutes).
  • the aqueous layer was separated and washed with ethyl acetate (300 ml).
  • the combined ethyl acetate layers were combined and washed with 1M HCl (300 ml), saturated sodium bicarbonate (400 ml), and brine (200 ml).
  • the organic layer was dried with magnesium sulfate, treated with Darco decolorizing charcoal and filtered. The solvent was removed under reduced pressure, yielding 21.48 g of the title compound (98% yield).
  • Triphenylphosphine (Aldrich, 5.7 g) was added to a solution of 2-cyano-5-(azidomethyl)thiophene (compound 3-4 , 2.5 g, 10 mmol) in THF (Aldrich, 40 ml) and water (10 ml) at 0°C. The solution was allowed to warm to room temperature and stirred at ambient temperature for 10 hours. RP-HPLC purification gave the title compound (2.3 g, 94%).
  • Example 99 Following the protocol of Example 98, with the noted substitution for isopropyl chloroformate, the following compounds are prepared: compound name Substitution in Example 99 n-butylsulfonyl-D-[(+)-menthyloxycarbonyl]-serine-alanine-4-amidinobenzylamide (+)-menthyl chloroformate n-butylsulfonyl-D-(phenoxycarbonyl)-serine-alanine-4-amidinobenzylamide phenyl chloroformate
  • rt-PA tissue plasminogen activator
  • the buffer used for all assays was HBSA (10 mM HEPES, pH 7.5, 150 mM sodium chloride, 0.1% bovine serum albumin).
  • the assay for IC 50 determinations was conducted by combining in appropriate wells of a Corning microtiter plate, 50 microliters of HBSA, 50 microliters of the test compound at a specified concentration (covering a broad concentration range) diluted in HBSA (or HBSA alone for V 0 (uninhibited velocity) measurement), and 50 microliters of the enzyme diluted in HBSA. Following a 30 minute incubation at ambient temperature, 50 microliters of the substrate at the concentrations specified below were added to the wells, yielding a final total volume of 200 microliters (about 4 times Km).
  • the initial velocity of chromogenic substrate hydrolysis was measured by the change in absorbance at 405 nm using a Thermo Max ® Kinetic Microplate Reader over a 5 minute period in which less than 5% of the added substrate was utilized.
  • the concentration of added inhibitor which caused a 50% decrease in the initial rate of hydrolysis was defined as the IC 50 value.
  • K i may be calculated from the IC 50 value.
  • Urokinase catalytic activity was determined using the chromogenic substrate 150 mM S-2444 (L-Pyroglutamyl-glycyl-L-arginine-p-nitroaniline hydrochloride), obtained from DiaPharma Group, Inc.
  • Urokinase (Abbokinase), manufactured by Abbott Laboratories, was obtained from Priority Pharmaceuticals and diluted to 750 pM in the HBSA assay buffer prior to use.
  • the assay buffer was HBS (10mM HEPES, 150mM sodium chloride pH 7.4) with 0.1% BSA. K i was calculated using the IC 50 value.
  • Enzyme activity was determined using the chromogenic substrate, Pefachrome t-PA (CH 3 SO 2 -D-hexahydrotyrosine-glycyl-L-Arginine-p-nitroaniline, obtained from Pentapharm Ltd.). The substrate was reconstituted in deionized water prior to use. Purified human ⁇ -thrombin was obtained from Enzyme Research Laboratories, Inc. The buffer used for all assays was HBSA (10 mM HEPES, pH 7.5, 150 mM sodium chloride, 0.1% bovine serum albumin).
  • IC 50 determinations were conducted where HBSA (50 ⁇ L), ⁇ -thrombin (50 ⁇ l) (the final enzyme concentration is 0.5 nM) and inhibitor (50 ⁇ l) (covering a broad concentration range), were combined in appropriate wells and incubated for 30 minutes at room temperature prior to the addition of substrate Pefachrome-t-PA (50 ⁇ l) (the final substrate concentration is 250 ⁇ M, about 5 times Km).
  • the initial velocity of Pefachrome t-PA hydrolysis was measured by the change in absorbance at 405nm using a Thermo Max ® Kinetic Microplate Reader over a 5 minute period in which less than 5% of the added substrate was utilized.
  • the concentration of added inhibitor which caused a 50% decrease in the initial rate of hydrolysis was defined as the IC 50 value.
  • Factor Xa catalytic activity was determined using the chromogenic substrate S-2765 (N-benzyloxycarbonyl-D-arginine-L-glycine-L-arginine-p-nitroaniline), obtained from DiaPharma Group (Franklin, OH). All substrates were reconstituted in deionized water prior to use. The final concentration of S-2765 was 250 ⁇ M (about 5-times Km).
  • Purified human Factor X was obtained from Enzyme Research Laboratories, Inc. (South Bend, IN) and Factor Xa (FXa) was activated and prepared from it as described [Bock, P.E., Craig, P.A., Olson, S.T., and Singh, P., Arch. Biochem. Biophys. 273 :375-388 (1989)]. The enzyme was diluted into HBSA prior to assay in which the final concentration was 0.25 nM.
  • rt-PA catalytic activity was determined using the substrate, Pefachrome t-PA (CH 3 SO 2 -D-hexahydrotyrosine-glycyl-L-arginine-p-nitroaniline, obtained from Pentapharm Ltd.).
  • the substrate was made up in deionized water followed by dilution in HBSA prior to the assay in which the final concentration was 500 micromolar (about 3-times Km).
  • Human rt-PA (Activase ® ) was obtained from Genentech Inc. The enzyme was reconstituted in deionized water and diluted into HBSA prior to the assay in which the final concentration was 1.0 nM.
  • Plasmin catalytic activity was determined using the chromogenic substrate, S-2366 [L-pyroglutamyl-L-prolyl-L-arginine-p-nitroaniline hydrochloride], which was obtained from DiaPharma Group.
  • the substrate was made up in deionized water followed by dilution in HBSA prior to the assay in which the final concentration was 300 micromolar (about 2.5-times Km).
  • Purified human plasmin was obtained from Enzyme Research Laboratories, Inc. The enzyme was diluted into HBSA prior to assay in which the final concentration was 1.0 nM.
  • aPC catalytic activity was determined using the chromogenic substrate, Pefachrome PC (delta-carbobenzyloxy-D-lysine-L-prolyl-L-arginine-p-nitroaniline dihydrochloride), obtained from Pentapharm Ltd.).
  • the substrate was made up in deionized water followed by dilution in HBSA prior to the assay in which the final concentration was 400 micromolar (about 3 times Km).
  • Purified human aPC was obtained from Hematologic Technologies, Inc. The enzyme was diluted into HBSA prior to assay in which the final concentration was 1.0 nM.
  • Chymotrypsin catalytic activity was determined using the chromogenic substrate, S-2586 (methoxy-succinyl-L-arginine-L-prolyl-L-tyrosyl-p-nitroanilide), which was obtained from DiaPharma Group.
  • the substrate was made up in deionized water followed by dilution in HBSA prior to the assay in which the final concentration was 100 micromolar (about 9-times Km).
  • Purified (3X-crystallized; CDI) bovine pancreatic ⁇ -chymotrypsin was obtained from Worthington Biochemical Corp.
  • the enzyme was reconstituted in deionized water and diluted into HBSA prior to assay in which the final concentration was 0.5 nM.
  • Trypsin catalytic activity was determined using the chromogenic substrate, S-2222 (benzoyl-L-isoleucine-L-glutamic acid-[gamma-methyl ester]-L-arginine-p-nitroanilide), which was obtained from DiaPharma Group.
  • the substrate was made up in deionized water followed by dilution in HBSA prior to the assay in which the final concentration was 250 micromolar (about 4-times Km).
  • Purified (3X-crystallized; TRL3) bovine pancreatic trypsin was obtained from worthington Biochemical Corp.
  • the enzyme was reconstituted in deionized water and diluted into HBSA prior to assay in which the final concentration was 0.5 nM.
  • Table I lists the determined K i or IC 50 values for certain of the enzymes listed above for compounds of the present invention that demonstrate a high degree of specificity for the inhibition of urokinase compared to other serine proteases.
  • Table I Compound Ki uPA* IC50 tPA* IC50 Plasmin* A A D D B C D E C C E D D B D D E A E NT P A E NT G B D E H B D D D I A D D J A D C K A D C L A D D D M B E E N A D D D O A D D D P A E D Q A E D R A E D S B E E T A D C U A C C V A D C W B E E X A D D Y A D D Z A E D AA A E D AB A E D AC B E E AD A D C AE A C C C AF A D C AG A E E AH A C D AI B E E AJ A D D D AK A D D AL A D D AM A E
  • the chicken CAM (chick embryo chorioallantoic membrane) model a standard angiogenesis assay, is used to evaluate the ability of a test compound to inhibit angiogenesis.
  • This model is an established model for evaluation of activity of a test compound to affect formulation of new blood vessels.
  • a filter disc saturated with a 0.5 ⁇ g/ml solution of basic fibroblast growth factor (bFGF) is placed on the CAM of 10 day old chick embryos to induce angiogenesis. Twenty four hours later, 0 to 1 ⁇ g of Test Compound, in a total volume of 100 ⁇ l of sterile PBS, is injected intravenously into the embryo. Approximately 48 hours later, the embryos are sacrificed and the filter discs and surrounding CAM tissue are excised for analysis. Angiogenesis is quantitated by counting the number of blood vessel branch points within the confined region of the filter [Brooks, P.C., et al, Methods in Molecular Biology 120: 257-269 (1999)]. The angiogenic index is defined as the difference in the number of blood vessel branch points between an experimental group and the untreated, control embryos. Each experimental group will contain 8 to 10 chicken embryos.
  • bFGF basic fibroblast growth factor
  • a chicken embryo model is used to evaluate the activity of Test Compound to inhibit the growth of human tumor cells in vivo .
  • a single cell suspension of human fibrosarcoma cells (HT 1080), containing 4 X 10 5 cells in a total volume of 40 ⁇ l, is applied to 10 day old chick embryos as described by Brooks, et al ("Brooks, P.C., et al, "Integrin ⁇ v ⁇ 3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels", Cell 79 :1157-1164 (1994)). Twenty-four hours later 0 to 10 ⁇ g of Test Compound are injected intravenously into the embryos.
  • control and treated embryos are incubated for a total of 7 days and then sacrificed. Tumors are excised, trimmed free of surrounding CAM tissue, and weighed. The wet weights for tumors excised in this experiment are tabulated. Each experimental group will contain 10 to 12 chicken embryos.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00126874A 2000-08-11 2000-12-07 Non-covalent inhibitors of urokinase and blood vessel formation Expired - Lifetime EP1182207B1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP07006986A EP1808440B1 (en) 2000-08-11 2000-12-07 Non-covalent inhibitors of urokinase and blood vessel formation
NZ547626A NZ547626A (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation
NZ518195A NZ518195A (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation
JP2002519486A JP2004506648A (ja) 2000-08-11 2001-08-10 ウロキナーゼおよび血管形成の非共有結合性インヒビター
NZ538572A NZ538572A (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation
PCT/US2001/025337 WO2002014349A2 (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation
AU83347/01A AU785260B2 (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation
IL14904201A IL149042A0 (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation
KR1020027004637A KR100879673B1 (ko) 2000-08-11 2001-08-10 유로키나제와 혈관 형성의 비공유적 억제제
CA002387002A CA2387002A1 (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation
IL149042A IL149042A (en) 2000-08-11 2002-04-09 Non-covalent inhibitors of urokinase and vascular formation
AU2006235835A AU2006235835B2 (en) 2000-08-11 2006-11-03 Non-covalent inhibitors of urokinase and blood vessel formation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63748300A 2000-08-11 2000-08-11
US637483 2000-08-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07006986A Division EP1808440B1 (en) 2000-08-11 2000-12-07 Non-covalent inhibitors of urokinase and blood vessel formation

Publications (3)

Publication Number Publication Date
EP1182207A2 EP1182207A2 (en) 2002-02-27
EP1182207A3 EP1182207A3 (en) 2002-09-04
EP1182207B1 true EP1182207B1 (en) 2007-04-18

Family

ID=24556134

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00126874A Expired - Lifetime EP1182207B1 (en) 2000-08-11 2000-12-07 Non-covalent inhibitors of urokinase and blood vessel formation
EP07006986A Expired - Lifetime EP1808440B1 (en) 2000-08-11 2000-12-07 Non-covalent inhibitors of urokinase and blood vessel formation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP07006986A Expired - Lifetime EP1808440B1 (en) 2000-08-11 2000-12-07 Non-covalent inhibitors of urokinase and blood vessel formation

Country Status (8)

Country Link
US (1) US6586405B2 (es)
EP (2) EP1182207B1 (es)
KR (1) KR100879673B1 (es)
AT (2) ATE517910T1 (es)
DE (1) DE60034447T2 (es)
ES (1) ES2285989T3 (es)
IL (1) IL149042A (es)
ZA (1) ZA200202825B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
JP4179878B2 (ja) * 2001-02-02 2008-11-12 中外製薬株式会社 ペプチド誘導体
JP2004520399A (ja) * 2001-02-09 2004-07-08 メルク　エンド　カムパニー　インコーポレーテッド トロンビン阻害剤
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
NZ527971A (en) 2001-03-27 2006-03-31 Dendreon Corp Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) * 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
AU2002364713A1 (en) * 2001-12-04 2003-06-17 Corvas International, Inc. Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
US7838560B2 (en) * 2002-03-11 2010-11-23 The Medicines Company (Leipzig) Gmbh Urokinase inhibitors, production and use thereof
US7019019B2 (en) * 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE10323898A1 (de) 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
CA2612262A1 (en) 2005-06-24 2006-12-28 Wilex Ag Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
WO2008148057A2 (en) 2007-05-23 2008-12-04 Vical Incorporated Cationic lipids compositions and methods for enhancing immune responses to vaccines
US20090155337A1 (en) * 2007-11-12 2009-06-18 Endologix, Inc. Method and agent for in-situ stabilization of vascular tissue
US20100261662A1 (en) * 2009-04-09 2010-10-14 Endologix, Inc. Utilization of mural thrombus for local drug delivery into vascular tissue
DE102009022794A1 (de) * 2009-05-27 2010-12-02 Philipps-Universität Marburg Verwendung von Hemmstoffen der HAT und TMPRSS2 als Arzneimittel
WO2011044455A1 (en) * 2009-10-09 2011-04-14 Vatrix Medical, Inc. In vivo chemical stabilization of vulnerable plaque
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
WO2012158944A1 (en) 2011-05-18 2012-11-22 Vatrix Medical, Inc. Coated balloons for blood vessel stabilization
US9283241B2 (en) 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
EP2960232A1 (en) * 2014-06-25 2015-12-30 DSM IP Assets B.V. Process for the production of a dipeptide derivative
US9777116B2 (en) 2014-10-16 2017-10-03 International Business Machines Corporation Porous/nanoporous PHT
CN113135842A (zh) * 2018-09-25 2021-07-20 四川什邡市三高生化实业有限公司 一种o-叔丁基-l-丝氨酸甲酯及o-叔丁基-l-丝氨酸水溶液的制备方法
JP2022541398A (ja) 2019-07-08 2022-09-26 リゾルート，インコーポレイティド 血漿カリクレイン阻害薬の調製プロセス
CN114269431A (zh) * 2019-08-21 2022-04-01 卡尔维斯塔制药有限公司 酶抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
CA2140598C (en) 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
DE4443390A1 (de) * 1994-12-06 1996-06-13 Basf Ag Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
CA2210989A1 (en) * 1995-02-10 1996-08-15 Basf Aktiengesellschaft Thrombin inhibitors
US6576613B1 (en) * 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
WO2000061608A2 (de) * 1999-04-09 2000-10-19 Basf Aktiengesellschaft Niedermolekulare inhibitoren von komplementproteasen
DE10029015A1 (de) * 2000-06-15 2001-12-20 Curacyte Ag Hemmstoffe für den Gerinnungsfaktor Xa
DE10029014A1 (de) 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe

Also Published As

Publication number Publication date
EP1808440A1 (en) 2007-07-18
DE60034447D1 (de) 2007-05-31
IL149042A (en) 2011-01-31
EP1182207A2 (en) 2002-02-27
ATE360028T1 (de) 2007-05-15
KR100879673B1 (ko) 2009-01-21
EP1182207A3 (en) 2002-09-04
ZA200202825B (en) 2003-07-10
US20020037857A1 (en) 2002-03-28
DE60034447T2 (de) 2008-02-14
EP1808440B1 (en) 2011-07-27
ES2285989T3 (es) 2007-12-01
ATE517910T1 (de) 2011-08-15
KR20020063562A (ko) 2002-08-03
US6586405B2 (en) 2003-07-01

Similar Documents

Publication Publication Date Title
EP1182207B1 (en) Non-covalent inhibitors of urokinase and blood vessel formation
AU2006235835B2 (en) Non-covalent inhibitors of urokinase and blood vessel formation
US6432922B1 (en) Inhibitors of urokinase and blood vessel formation
EP0664786B1 (en) Arginine keto-amide enzyme inhibitors
EP0765340B1 (en) Methionine sulfone and s-substituted cysteine sulfone derivatives as enzyme inhibitors
AU716995B2 (en) N-substituted glycine derivatives as inhibitors of factor Xa
EP0765339A1 (en) 3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
WO1995035311A9 (en) 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
WO1995035311A1 (en) 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
US7262211B2 (en) Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
WO2001079261A1 (en) Tetrahydro-azepinone derivatives as thrombin inhibitors
EP0765338B1 (en) Arginine mimic derivatives as enzyme inhibitors
CZ2001276A3 (cs) Inhibitory urokinázy a farmaceutický prostředek, který je obsahuje
AU2863095A (en) 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 5/062 A, 7C 07K 5/06 B, 7A 61K 38/05 B

17P Request for examination filed

Effective date: 20030129

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20040614

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DENDREON CORPORATION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070418

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60034447

Country of ref document: DE

Date of ref document: 20070531

Kind code of ref document: P

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: WILEX AG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070718

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: WILEX AG

Effective date: 20070613

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070918

ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VOSSIUS & PARTNER

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2285989

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070418

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070418

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: VOSSIUS & PARTNER;NADELBERG 3;4051 BASEL (CH)

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

26N No opposition filed

Effective date: 20080121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070418

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20101214

Year of fee payment: 11

Ref country code: FR

Payment date: 20110104

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20101224

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20101221

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20101015

Year of fee payment: 11

Ref country code: IT

Payment date: 20101227

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20101223

Year of fee payment: 11

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20111207

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120831

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60034447

Country of ref document: DE

Effective date: 20120703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111207

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111207

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 360028

Country of ref document: AT

Kind code of ref document: T

Effective date: 20111207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120102

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111208